Oncology
HER2-Positive Advanced Solid Tumors
0
Pipeline Programs↗
2
Active Trials↗
5
Companies Involved↗
HER2-positive Advanced Solid Tumors is an early-stage landscape with 0 programs across 5 companies. The most active players are Suzhou Zanrong Pharma Limited, Hangzhou Adcoris Biopharmacy Co., Ltd, Wuhan YZY Biopharma Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
9
clinical trials
Unknown status4 · 44%
Completed2 · 22%
Enrolling by invitation1 · 11%
Recruiting1 · 11%
Terminated1 · 11%
Clinical Trials
Trial Activity
9 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)